Payment overview · 2025
General Payments
$2,157.30
62 reported records · 13 companies
Healthcare provider profile · identity verified
Singmay Siu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1306986351
Verified facts
What the public records show
CMS Open Payments records show Singmay Siu, M.D. received $2,157.30 in general payments during 2025 across 62 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Prolia, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 434 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 434 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $707.82 | 32.8% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $484.18 | 22.4% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $286.61 | 13.3% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.62 | 8.6% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $184.02 | 8.5% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $72.66 | 3.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.34 | 3.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.15 | 2.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.04 | 1.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.08 | 1.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.48 | 1.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.01 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.29 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,157.30 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $722.11 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $244.40 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $234.72 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $217.81 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $184.02 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $177.01 | 8 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $72.66 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $72.66 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $69.34 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.52 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.98 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.04 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.23 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 269 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 434 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 268 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 28 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 118 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
268 | 55 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
269 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
71 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
434 | 72 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
84 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
434 | 72 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
118 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 2174 | 332 |
| Simvastatin | Simvastatin | 1620 | 239 |
| Metformin Hcl | Metformin Hcl | 1278 | 207 |
| Omeprazole | Omeprazole | 1131 | 273 |
| Losartan Potassium | Losartan Potassium | 1082 | 192 |
| Atorvastatin Calcium | Atorvastatin Calcium | 966 | 212 |
| Vascepa | Icosapent Ethyl | 836 | 212 |
| Tamsulosin Hcl | Tamsulosin Hcl | 812 | 132 |
| Donepezil Hcl | Donepezil Hcl | 663 | 112 |
| Meclizine Hcl | Meclizine Hcl | 620 | 232 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 518 | 115 |
| Meloxicam | Meloxicam | 508 | 222 |
| Trazodone Hcl | Trazodone Hcl | 497 | 192 |
| Alendronate Sodium | Alendronate Sodium | 459 | 74 |
| Glimepiride | Glimepiride | 457 | 72 |
| Jardiance | Empagliflozin | 434 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 418 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 399 | 118 |
| Hydrocortisone | Hydrocortisone | 391 | 152 |
| Azithromycin | Azithromycin | 390 | 225 |
| Fluticasone Propionate | Fluticasone Propionate | 381 | 155 |
| Gabapentin | Gabapentin | 377 | 94 |
| Atenolol | Atenolol | 321 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 307 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 303 | 66 |
| Montelukast Sodium | Montelukast Sodium | 283 | 55 |
| Farxiga | Dapagliflozin Propanediol | 269 | 45 |
| Halobetasol Propionate | Halobetasol Propionate | 268 | 125 |
| Linzess | Linaclotide | 268 | 55 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 263 | 117 |
| Finasteride | Finasteride | 261 | 37 |
| Ammonium Lactate | Ammonium Lactate | 258 | 131 |
| Azelastine Hcl | Azelastine Hcl | 253 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 63 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 201 | 55 |
| Amoxicillin | Amoxicillin | 181 | 110 |
| Januvia | Sitagliptin Phosphate | 180 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 172 | 36 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 162 | 74 |
| Pioglitazone Hcl | Pioglitazone Hcl | 161 | 31 |
| Mometasone Furoate | Mometasone Furoate | 160 | 51 |
| Icosapent Ethyl | Icosapent Ethyl | 147 | 80 |
| Loperamide | Loperamide Hcl | 145 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 26 |
| Furosemide | Furosemide | 141 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 21 |
| Rybelsus | Semaglutide | 118 | 16 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 115 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 21 |
| Dexlansoprazole Dr | Dexlansoprazole | 99 | 28 |
| Colchicine | Colchicine | 93 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 24 |
| Famotidine | Famotidine | 92 | 24 |
| Ketoconazole | Ketoconazole | 86 | 28 |
| Allopurinol | Allopurinol | 85 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 85 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 84 | 52 |
| Gemfibrozil | Gemfibrozil | 83 | 12 |
| Procto-Med Hc | Hydrocortisone | 83 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 81 | 60 |
| Tradjenta | Linagliptin | 81 | 12 |
| Lisinopril | Lisinopril | 80 | 12 |
| Celecoxib | Celecoxib | 79 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 75 | 11 |
| Ezetimibe | Ezetimibe | 73 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 71 | 16 |
| Nexium | Esomeprazole Magnesium | 71 | 13 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 70 | 29 |
| Clobetasol Propionate | Clobetasol Propionate | 69 | 43 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 67 | 19 |
| Glipizide Er | Glipizide | 66 | suppressed |
| Valsartan | Valsartan | 65 | 14 |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Nitroglycerin | Nitroglycerin | 63 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 50 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 59 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 57 | 26 |
| Clotrimazole | Clotrimazole | 54 | 20 |
| Entecavir | Entecavir | 54 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 13 |
| Eliquis | Apixaban | 52 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 49 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | 16 |
| Dapagliflozin | Dapagliflozin Propanediol | 47 | 22 |
| Diclofenac Epolamine | Diclofenac Epolamine | 42 | 27 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 42 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 39 | 16 |
| Carvedilol | Carvedilol | 38 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 32 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 36 | 17 |
| Prednisone | Prednisone | 33 | 15 |
| Acarbose | Acarbose | 31 | suppressed |
| Rivastigmine | Rivastigmine | 31 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Prolia | Denosumab | 28 | 16 |
| Fluocinonide | Fluocinonide | 27 | 14 |
| Mupirocin | Mupirocin | 26 | 18 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ursodiol | Ursodiol | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Proctozone-Hc | Hydrocortisone | 20 | suppressed |
| Silodosin | Silodosin | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 19 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 19 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Nateglinide | Nateglinide | 18 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 17 | 11 |
| Baclofen | Baclofen | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Benzonatate | Benzonatate | 15 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,157.30 · 62 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, BREZTRI, CAPVAXIVE, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, Fluad, Flucelvax, GARDASIL 9, JARDIANCE, Kerendia, LINZESS, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus, SHINGRIX, VOQUEZNA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error